Every article on this site is written by AI from official sources and checked by a second AI. How it works

CDC reports later RSV season, COVID-19 peaks in 2025–26

Part of our Public Health coverage: background and related stories

The Centers for Disease Control and Prevention reported later-than-usual respiratory syncytial virus activity and two national COVID-19 peaks during July 2025 through June 2026. The agency said RSV severity was lower than in recent years and most sequenced U.S. SARS-CoV-2 viruses were JN.1 descendants.

RSV season onset occurred the week ending Nov. 29, 2025, peaked the week ending Feb. 28, 2026, and ended the week ending April 25, 2026, according to the CDC. The report says these milestones occurred later nationally and by region than in past seasons. COVID-19 test positivity peaked nationally in the weeks ending Aug. 23, 2025, and Jan. 24, 2026.

Hospitalization rates by virus and age group, July 2025–June 2026
VirusAge groupRate per 100,000
RSVInfants 0–11 months790.2
RSVChildren 12–23 months611.9
RSVAdults ≥75 years352.1
COVID-19Adults ≥75 years361.2
COVID-19Infants <6 months173.3
COVID-19Adults 65–74 years111.4
COVID-19Children 6–23 months67.3
Source: CDC Morbidity and Mortality Weekly Report.

RSV was linked to an estimated 2.8 million to 5.8 million outpatient visits, 170,000 to 340,000 hospitalizations, and 9,900 to 25,000 deaths nationwide during the period. COVID-19 resulted in an estimated 4.1 million to 12.4 million illnesses, 830,000 to 2.3 million outpatient visits, 130,000 to 240,000 hospitalizations, and 14,000 to 41,000 deaths, nationally. The CDC described these as interim modeling estimates.

RSV-associated hospitalization rates were highest among infants aged younger than 12 months (790.2 per 100,000), children aged 12 to 23 months (611.9), and adults aged 75 years and older (352.1). The CDC said overall RSV hospitalization rates in 2025–2026 (97.3 per 100,000) were lower than during 2022–2025. COVID-19 hospitalization rates were highest among adults aged 75 years and older (361.2 per 100,000), infants younger than 6 months (173.3), adults aged 65 to 74 years (111.4), and children aged 6 to 23 months (67.3).

Provisional pediatric mortality surveillance identified 34 RSV-associated deaths from 35 reporting jurisdictions between Sept. 28, 2025, and June 30, 2026. The median age at death was 1 year. The CDC said 31 COVID-19–associated pediatric deaths were reported from 43 jurisdictions in the same period, with a median age at death of 9 months. The agency noted these counts are provisional and likely underestimates.

RSV sequencing found no substitutions linked to reduced susceptibility to available infant monoclonal antibodies, the report says. Among SARS-CoV-2 samples, most lineages were JN.1 descendants; the CDC reported no major strain replacement for a second year. Detections of the divergent BA.3.2 variant increased, and the agency said it is monitoring BA.3.2 spread through genomic surveillance.

Other respiratory viruses largely followed historical patterns. According to the CDC, being up to date on recommended RSV and COVID-19 vaccines lowers the chance of severe illness.

  1. Respiratory Virus Activity - United States, July 2025-June 2026 — CDC Morbidity and Mortality Weekly Report
How this article was made
Written with
GPT-5 (OpenAI)
Fact-checked by
Gemini 3.1 Pro (Google) — passed
Generated
Nov. 19, 2026, 6:09 p.m. ET
Sources used
1 official source, listed above
Article type
Standard

The AI wrote only from the sources listed. No human reporter was involved. Read our standards or compare the models in the AI Report Card.